Discovery of NO Donor-Aurovertin Hybrids as Dual Ferroptosis and Apoptosis Inducers for Treating Triple Negative Breast Cancer

被引:5
|
作者
Ma, Lie-Feng [1 ]
Xu, Li-Li [2 ]
Yuan, Ling-Jie [1 ]
Yang, Xi [1 ]
Wu, Rui [4 ]
Bao, Shu-Min [1 ]
Chen, Yi-Li [1 ]
Duan, Hong-Liang [5 ]
Fang, Luo [3 ]
Zhao, Hua-Jun [2 ]
Zhan, Zha-Jun [1 ]
机构
[1] Zhejiang Univ Technol, Coll Pharmaceut Sci, Key Lab Green Pharmaceut Technol & Related Equipme, Minist Educ, Hangzhou 310014, Peoples R China
[2] Zhejiang Chinese Med Univ, Sch Pharmaceut Sci, Hangzhou 311402, Peoples R China
[3] Zhejiang Canc Hosp, Dept Pharm, Hangzhou 310022, Peoples R China
[4] Univ Chinese Acad Sci, Hangzhou Inst Adv Study, Sch Pharmaceut Sci & Technol, Hangzhou 310024, Peoples R China
[5] Macao Polytech Univ, Fac Appl Sci, Taipa 999078, Macao, Peoples R China
基金
中国国家自然科学基金;
关键词
aurovertin; triple negative breast cancer; NO donor; ferroptosis; anti-metastasis; OXIDE-RELEASING DERIVATIVES; ATP SYNTHASE; MONOCLONAL-ANTIBODY; IN-VITRO; CARCINOMA; CELLS; POLYKETIDES; INHIBITION; THERAPY; DESIGN;
D O I
10.1021/acs.jmedchem.4c01070
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Triple-negative breast cancer (TNBC) is a highly lethal malignancy, and its clinical management encounters severe challenges due to its high metastatic propensity and the absence of effective therapeutic targets. To improve druggability of aurovertin B (AVB), a natural polyketide with a significant antiproliferative effect on TNBC, a series of NO donor/AVB hybrids were synthesized and tested for bioactivities. Among them, compound 4d significantly inhibited the proliferation and metastasis of TNBC in vitro and in vivo with better safety than that of AVB. The structure-activity relationship analysis suggested that the types of NO donor and the linkers had considerable effects on the activities. Mechanistic investigations unveiled that 4d induced apoptosis and ferroptosis by the reduction of mitochondrial membrane potential and the down-regulation of GPX4, respectively. The antimetastatic effect of 4d was associated with the upregulation of DUSP1. Overall, these compelling results underscore the tremendous potential of 4d for treating TNBC.
引用
收藏
页码:13089 / 13105
页数:17
相关论文
共 50 条
  • [41] Discovery of dual PARP/NAMPT inhibitors for the treatment of BRCA wild-type triple-negative breast cancer
    Mao, Jie
    Wang, Kaizhen
    Tong, Jun
    Zhang, Wanheng
    Shen, Guoqing
    Wang, Dexiang
    Liao, Zepeng
    Zhang, Zhiyi
    Miao, Qi
    Jiang, Sheng
    Zhang, Kuojun
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2025, 120
  • [42] Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment
    Masci, Domiziana
    Naro, Chiara
    Puxeddu, Michela
    Urbani, Andrea
    Sette, Claudio
    La Regina, Giuseppe
    Silvestri, Romano
    MOLECULES, 2023, 28 (22):
  • [43] New insights into the discovery of drugs for triple-negative breast cancer metastasis
    Altei, Wanessa Fernanda
    Pachane, Bianca Cruz
    Souza, Cristiano
    Marques, Marcia Maria Chiquitelli
    Selistre-de-Araujo, Heloisa
    EXPERT OPINION ON DRUG DISCOVERY, 2022, 17 (04) : 365 - 376
  • [44] Discovery of a small molecule inhibitor for triple-negative breast cancer (TNBC)
    Saran, Uttara
    Chandrasekaran, Balaji
    Tyagi, Ashish
    Singh, Amandeep
    Ankem, Murali K.
    Sharma, Arun K.
    Damodaran, Chendil
    CANCER RESEARCH, 2022, 82 (12)
  • [45] Enhancer mapping in triple negative breast cancer as a tool for biomarker and oncogene discovery
    Raisner, Ryan
    Bainer, Russell
    Gascoigne, Karen
    CANCER RESEARCH, 2019, 79 (13)
  • [46] Discovery of novel chloropyramine-cinnamic acid hybrids as potential FAK inhibitors for intervention of metastatic triple-negative breast cancer
    Yang, Fei
    Xu, Kangping
    Zhang, Sha
    Zhang, Jinlin
    Qiu, Yaoren
    Luo, Jin
    Tan, Guishan
    Zou, Zhenxing
    Wang, Wenxuan
    Kang, Fenghua
    BIOORGANIC & MEDICINAL CHEMISTRY, 2022, 66
  • [47] Conceptualizing the complexity of ferroptosis to treat triple-negative breast cancer:theory-to-practice
    Hang Zhang
    Fan Yang
    Yi Xiao
    YiZhou Jiang
    ZhiMing Shao
    Cancer Biology & Medicine, 2023, 20 (02) : 98 - 103
  • [48] Ferroptosis Heterogeneity in Triple-Negative Breast Cancer Reveals an Innovative Immunotherapy Combination Strategy
    Yang, Fan
    Xiao, Yi
    Ding, Jia-Han
    Jiang, Yi-Zhou
    Shao, Zhi-Ming
    CANCER RESEARCH, 2023, 83 (05)
  • [49] Conceptualizing the complexity of ferroptosis to treat triple-negative breast cancer: theory-to-practice
    Zhang, Hang
    Yang, Fan
    Xiao, Yi
    Jiang, Yi-Zhou
    Shao, Zhi-Ming
    CANCER BIOLOGY & MEDICINE, 2023, 20 (02) : 98 - 103
  • [50] Targeted exosome-encapsulated erastin induced ferroptosis in triple negative breast cancer cells
    Yu, Mengyu
    Gai, Chengcheng
    Li, Zihaoran
    Ding, Dejun
    Zheng, Jie
    Zhang, Weifen
    Lv, Shijun
    Li, Wentong
    CANCER SCIENCE, 2019, 110 (10) : 3173 - 3182